

令和元(2019)年度 研究成果の刊行に関する一覧表 【書籍】

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ	関連
1) 芥田憲夫 熊田博光	肝疾患治療薬－B型・C型 肝炎における抗ウイルス 療法・抗炎症療法	高久史磨	治療薬ハン ドブック 2019	じほう	東京	2019	582-587	
2) 宮坂昭生,黒田英 克,及川隆喜,柿坂 啓介,吉田雄一,遠 藤啓,鈴木悠地,佐 藤寛毅,阿部珠美, 藤原裕大,岡本卓 也,米澤美希,滝川 康裕.	当科における肝硬変の成 因別実態	西口修平	肝硬変の成 因別実態 2018	医学図書 出版	東京	2019	36-37	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
1)	Kumada T, Toyoda H, Tada T, Yasuda S, Miyake N, <a href="#">Tanaka J</a>	Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels	European journal of gastroenterology and hepatology			in press	○
2)	Tada T, Toyoda H, Yasuda S, Kumada T, Kurisu A, Ohisa M, Akita T, <a href="#">Tanaka J</a>	Long-term prognosis of liver disease in patients with eradicated chronic hepatitis C virus: an analysis using a Markov chain model	Hepatology Research			in press	○
3)	Fukami Y, Kaneoka Y, Maeda A, Kumada T, <a href="#">Tanaka J</a> , Akita T, Kubo S, Izumi N, Kadoya M, Sakamoto M, Nakashima O, Matsuyama Y, Kokudo T, Hasegawa K, Yamashita T, Kashiwabara K, Takayama T, Kokudo N, Kudo M, Liver Cancer Study Group of Japan	Liver Resection for Multiple Hepatocellular Carcinomas: A Japanese Nationwide Survey	Annals of surgery			in press	○
4)	Akita T, <a href="#">Tanaka J</a> , Satake M, Lin Y, Wada T, Kato K, Inoue M	Meta-regression analysis of sex- and birth year-specific prevalence of HBsAg and anti-HCV among un-diagnosed Japanese: Data from the first-time blood donors, periodical health checkup, and the comprehensive health checkup with lifestyle education (Ningen Dock)	Journal of Epidemiology			in press	○
5)	Ko K, Takahashi K, Nagashima S, Yamamoto C, Ork V, Sugiyama A, Akita T, Ohisa M, Chuon C, Shafiqul Hossain M, Mao B, <a href="#">Tanaka J</a>	Existence of hepatitis B virus surface protein mutations and other variants: demand for hepatitis B infection control in Cambodia	BMC Infectious Disease	25(1)	305	2020	○
6)	Tada T, Kumada T, Toyoda H, Yasuda S, Sone Y, Hashinokuchi S, Ogawa S, Oguri T, Kamiyama N, Chuma M, Akita T, <a href="#">Tanaka J</a>	Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis	Hepatology Research	50(2)	190-198	2020	○
7)	Lingani M, Akita T, Ouoba S, Nagashima S, Boua PR, Takahashi K, Kam B, Sugiyama A, Nikiema T, Yamamoto C, Some A, Derra K, Ko K, Sorgho H, Tanagda Z, Tinto H, <a href="#">Tanaka J</a>	The changing epidemiology of hepatitis B and C infections in Nanoro, rural Burkina Faso: A multistage stratified random sampling survey	BMC Infectious Disease	20(1)	46	2020	○
8)	Yamamoto C, Nagashima S, Isomura M, Ko K, Chuon C, Akita T, Katayama K, Woodring J, Hossain MS, Takahashi K, <a href="#">Tanaka J</a>	Evaluation of the efficiency of dried blood spot-based measurement of hepatitis B and hepatitis C virus seromarkers	Scientific Reports	10(1)	3857	2020	○
9)	Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, <a href="#">Tanaka J</a>	Natural history of liver-related disease in patients with chronic hepatitis C virus infection: an analysis using a Markov chain model	Journal of Medical Virology	91(10)	1837-1844	2019	○
10)	Mizuno K, Toyoda H, Yasuda S, Tada T, Kumada T, Sone Y, <a href="#">Tanaka J</a>	The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma	Journal of Gastroenterology	54(9)	829-836	2019	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
11)	Toyoda H, Tada T, Yasuda S, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, <a href="#">Tanaka J</a> , Kumada T	The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C	Alimentary Pharmacology and Therapeutics	50(11-12)	1232	2019	○
12)	<a href="#">Tanaka J</a> , Akita T, Ko K, Miura Y, Satake M; Epidemiological research group on Viral hepatitis and it's long term course, MHLW	Countermeasures against viral hepatitis B and C in Japan: From an epidemiological point of view	Hepatology Research	49(9)	990-1002	2019	○
13)	Honmyo N, Kobayashi T, Hamaoka M, Kohashi T, Abe T, Oishi K, Tazawa H, Imaoka Y, Akita T, <a href="#">Tanaka J</a> , Ohdan H, Hiroshima Surgical study group of Clinical Oncology (HiSCO)	Comparison of new prognostic systems for patients with resectable hepatocellular carcinoma: Albumin-Bilirubin grade and Albumin-Indocyanine Green Evaluation grade	Hepatology Research	49(10)	1218-1226	2019	○
14)	Toyoda H, Kumada T, Tada T, Mizuno K, Sone Y, Akita T, <a href="#">Tanaka J</a> , Johnson PJ	The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study	Liver International	39(3)	448-454	2019	○
15)	Ork V, Woodring J, Shafiqul Hossain M, Wasley A, Nagashima S, Yamamoto C, Chuon C, Sugiyama A, Ohisa M, Akita T, Ko K, Mao B, <a href="#">Tanaka J</a>	Hepatitis B surface antigen seroprevalence among pre- and post-vaccine cohorts in Cambodia, 2017	Vaccine	37(35)	5059-5066	2019	○
16)	Nagashima S, Yamamoto C, Ko K, Chuon C, Sugiyama A, Ohisa M, Akita T, Katayama K, Yoshihara M, <a href="#">Tanaka J</a>	Acquisition rate of antibody to hepatitis B surface antigen among medical and dental students in Japan after three-dose hepatitis B vaccination	Vaccine	37(1)	145-151	2019	○
17)	Tada T, Kumada T, Toyoda H, Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, <a href="#">Tanaka J</a>	Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic	Journal of Gastroenterology and Hepatology	34(6)	1066-1073	2019	○
18)	Tada T, Toyoda H, Sone Y, Yasuda S, Miyake N, Kumada T, <a href="#">Tanaka J</a>	Type 2 diabetes mellitus is a risk factor for progression of liver fibrosis in middle-aged patients with nonalcoholic fatty liver disease	Journal of Gastroenterology and Hepatology	34(11)	2011-2018	2019	○
19)	Tada T, Toyoda H, Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, <a href="#">Tanaka J</a>	Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model	European Journal of Gastroenterology and Hepatology	31(11)	1452-1459	2019	○
20)	Hiramatsu A, Aikata H, Uchikawa S, Ohya K, Kodama K, Nishida Y, Daijo K, Osawa M, Teraoka Y, Honda F, Inagaki Y, Morio K, Morio R, Fujino H, Nakahara T, Murakami E, Yamauchi M, Kawaoka T, Miki D, Tsuge M, Imamura M, <a href="#">Tanaka J</a> , Chayama K	Levocarnitine use is associated with improvement in sarcopenia in patients with liver cirrhosis	Hepatology Communications	22(3)	348-355	2019	○
21)	Chuon C, Takahashi K, Matsuo J, Katayama K, Yamamoto C, Ko K, Hok S, Nagashima S, Akbar SMF, <a href="#">Tanaka J</a>	High possibility of hepatocarcinogenesis in HBV genotype C1 infected Cambodians is indicated by 340 HBV C1 full-genomes analysis from GenBank.	Scientific Reports	9(1)	12186	2019	○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
22)	Shimagaki T, Yoshio S, Kawai H, Sakamoto Y, Doi H, Matsuda M, Mori T, Osawa Y, Fukai M, Yoshida T, Ma Y, Akita T, <u>Tanaka J</u> , Taketomi A, Hanayama R, Yoshizumi T, Mori M, Kanto T	Serum milk fat globule-EGF factor 8 (MFG-E8) as a diagnostic and prognostic biomarker in patients with hepatocellular carcinoma	Scientific Reports	9(1)	15788	2019	○
23)	Yamamoto C, Ko K, Nagashima S, Harakawa T, Fujii T, Ohisa M, Katayama K, Takahashi K, Okamoto H, <u>Tanaka J</u>	Very low prevalence of anti-HAV in Japan: high potential for future outbreak	Scientific Reports	9(1)	1493	2019	○
24)	Sato T, Takemura A, Ikeyama Y, Sakamaki Y, Mimata A, Aoyagi H, <u>Aizaki H</u> , Sekine S, Ito K	Transmission electron microscopy of the benzbromarone-induced change in mitochondrial morphology in HepG2 cells.	Fundam. Toxicol. Sci.	6(8)	281-286.	2019	
25)	Watanabe N, Suzuki T, Date T, Hussan HA, Hmwe SS, <u>Aizaki H</u> , Sugiyama M, Mizokami M, Delaney Iv W, Cheng G, Muramatsu M, Wakita T.	Establishment of infectious genotype 4 cell culture-derived hepatitis C virus.	J Gen Virol.		doi: 10.1099 /jgv.0.001378.	2019	
26)	Iwamoto M, Saso W, Nishioka K, Ohashi H, Sugiyama R, Ryo A, Ohki M, Yun JH, Park SY, Ohshima T, Suzuki R, Aizaki H, Muramatsu M, Matano T, Iwami S, Sureau C, Wakita T, Watashi K.	The machinery for endocytosis of epidermal growth factor receptor coordinates the transport of incoming hepatitis B virus to the endosomal network.	J Biol Chem.		doi: 10.1074 /jbc.AC119.010366.	2019	
27)	Nakajima S, Watashi K, Fukano K, Tsukuda S, Wakae K, <u>Aizaki H</u> , Muramatsu M, Wakita T, Toyoda T.	Non-nucleoside hepatitis B virus polymerase inhibitors identified by an in vitro polymerase elongation assay.	J Gastroenterol.		doi: 10.1007 /s00535-019-01643-0.	2019	
28)	Kong L, Aoyagi H, Yang Z, Ouyang T, Matsuda M, Fujimoto A, Watashi K, Suzuki R, Arita M, Yamagoe S, Dohmae N, Suzuki T, Suzuki T, Muramatsu M, Wakita T, <u>Aizaki H</u> .	Surfeit 4 contributes to the replication of hepatitis C virus using double membrane vesicles.	J Virol.		doi: 10.1128 /JVI.00858-19.	2019	
29)	Hatanaka T, Naganuma A, Tateyama Y, Yoshinari F, Hoshino T, Sato K, Hmwe SS, <u>Aizaki H</u> , Wakita T, Kakizaki S, Uraoka T.	Ledipasvir and Sofosbuvir for Acute Hepatitis C Virus Mono-infection Associated with a High Risk of Acute Liver Failure: A Case Report.	Intern Med.		doi: 10.2169 /internalmedicine.2982-19.	2019	
30)	Iwamoto M, Saso W, Sugiyama R, Ishii K, Ohki M, Nagamori S, Suzuki R, <u>Aizaki H</u> , Ryo A, Yun JH, Park SY, Ohtani N, Muramatsu M, Iwami S, Tanaka Y, Sureau C, Wakita T, Watashi K.	Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization.	Proc Natl Acad Sci U S A.		doi: 10.1073 /pnas.1811064116.	2019	
31)	Suzuki R, Matsuda M, Shimoike T, Watashi K, <u>Aizaki H</u> , Kato T, Suzuki T, Muramatsu M, Wakita T.	Activation of protein kinase R by hepatitis C virus RNA-dependent RNA polymerase.	Virology.	529	226-233.	2019	
32)	Bang BR, Li M, Tsai KN, Aoyagi H, Lee SA, Machida K, <u>Aizaki H</u> , Jung JU, Ou JJ, Saito T.	Regulation of Hepatitis C Virus Infection by Cellular Retinoic Acid Binding Proteins through the Modulation of Lipid Droplet Abundance.	J Virol.		doi: 10.1128 /JVI.02302-18.	2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
33)	Fukano K, Tsukuda S, Oshima M, Suzuki R, <u>Aizaki H</u> , Ohki M, Park SY, Muramatsu M, Wakita T, Sureau C, Ogasawara Y, Watashi K.	Troglitazone Impedes the Oligomerization of Sodium Taurocholate Cotransporting Polypeptide and Entry of Hepatitis B Virus Into Hepatocytes.	Front Microbiol.		doi:10.3389/fmicb.	2019	
34)	<u>Akuta N</u> , Kawamura Y, Arase Y, Saitoh S, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Suzuki Y, Suzuki F, Ikeda K, Kumada H.	Circulating MicroRNA-122 and Fibrosis Stage Predict Mortality of Japanese Patients With Histopathologically Confirmed NAFLD	Hepatology Commun	4(1)	66-76	2019	
35)	<u>Akuta N</u> , Kawamura Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Predictors of Insulin Secretion in Japanese Patients With Histopathologically-confirmed Non-alcoholic Fatty Liver Disease	Intern Med		PMID:31534089	2019	
36)	<u>Akuta N</u> , Kawamura Y, Watanabe C, Nishimura A, Okubo M, Mori Y, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus.	Hepatology Res	49(5)	531-539	2019	
37)	<u>Akuta N</u> , Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Favorable efficacy of glecaprevir plus pibrentasvir as salvage therapy for HCV failures to prior direct-action antivirals regimens.	J Med Virol	91(1)	102-106	2019	
38)	<u>Akuta N</u> , Suzuki F, Sezaki H, Kobayashi M, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Saitoh S, Suzuki Y, Arase Y, Ikeda K, Kumada H	Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance	J Clin Microbiol	57(1)	1-11	2019	
39)	Hosaka T, Suzuki F, Kobayashi M, Fujiyama S, Kawamura Y, Sezaki H, <u>Akuta N</u> , Suzuki Y, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.	Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues.	Aliment Pharmacol Ther	49(4)	457-471	2019	
40)	Kawamura Y, Ikeda K, Shindoh J, Kobayashi Y, Kasuya K, Fujiyama S, Hosaka T, Kobayashi M, Saitoh S, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Hashimoto M, Kumada H	No-touch ablation in hepatocellular carcinoma has the potential to prevent intrasubsegmental recurrence to the same degree as surgical resection.	Hepatology Res	49(2)	164-176	2019	
41)	Ogasawara N, Saitoh S, <u>Akuta N</u> , Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Long-term outcome of HCC occurrence, esophageal varices exacerbation and mortality in hepatitis C virus-related liver cirrhosis after interferon-based therapy.	Hepatology Res	49(12)	1441-1450	2019	
42)	Ogasawara N, Saitoh S, <u>Akuta N</u> , Sezaki H, Suzuki F, Fujiyama S, Kawamura Y, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Kumada H.	Advantage of liver stiffness measurement before and after direct-acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C	Hepatology Res		PMID:31785120	2019	
43)	Ogasawara N, Saitoh S, Denpou H, Kinowaki K, <u>Akuta N</u> , Suzuki F, Hashimoto M, Fujiyama S, Kawamura Y, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Arase Y, Ikeda K, Fujii T, Kumada H.	Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient With an Otherwise Normal Liver	Intern Med		PMID31619599	2019	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
44) Ohya K,Saitoh S,Fujiyama S,Kawamura Y,Sezaki H,Hosaka T, <u>Akuta N</u> ,Kobayashi M,Kobayashi M,Suzuki F,Suzuki Y,Arase Y,Ikeda K,Kinowaki K,Fujii T,Kondo F,Kumada H.	Primary liver carcinoma with sarcomatous changes:Analysis of 10 cases.	Hepatol Res	49(6)	711-717	2019	
45) Sano T, <u>Akuta N</u> ,Suzuki F,Kasuya K,Fujiyama S,Kawamura Y,Sezaki H,Hosaka T,Saitoh S,Kobayashi M,Suzuki F,Kobayashi M,Arase Y,Ikeda K,Kumada H.	Role of NS5A-L31/Y93 double wild type in failure of glecaprevir/pibrentasvir double therapy in two patients with history of direct-acting antiviral agents failure:Ultra-deep sequencing analysis	Intern Med	58(18)	2657-2662	2019	
46) Sezaki H,Suzuki F,Hosaka T,Fujiyama S,Kawamura Y, <u>Akuta N</u> ,Kobayashi M,Suzuki Y,Saitoh S,Arase Y,Ikeda K,Kobayashi M,Kumada H.	Initial-and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections	J Gastroenterol	54(10)	916-927	2019	
47) Shindoh J,Kawamura Y,Kobayashi Y, <u>Akuta N</u> ,Kobayashi M,Suzuki Y,Ikeda K,Hashimoto M.	Time-to-Interventional Failure as a New Surrogate Measure for Survival Outcomes After Resection of Hepatocellular Carcinoma	J Gastrointest Surg		PMID:31190124	2019	
48) Shindoh J,Kawamura Y,Kobayashi Y,Kiya Y,Sugawara T, <u>Akuta N</u> ,Kobayashi M,Suzuki Y,Ikeda K,Hashimoto M.	Platelet-Albumin Score as a Sensitive Measure for Surgical Risk Prediction and Survival Outcomes of Patients With Hepatocellular Carcinoma	J Gastrointest Surg	23(1)	76-83	2019	
49) Suzuki F,Hosaka T,Suzuki Y,Sezaki H, <u>Akuta N</u> ,Fujiyama S,Kawamura Y,Kobayashi M,Saitoh S,Arase Y,Ikeda K,Kobayashi M,Mineta R,Suzuki Y,Kumada H	Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in Japan.	J Gastroenterol	54(2)	182-193	2019	
50) Suzuki H,Kawamura Y,Kinowaki K, <u>Akuta N</u> ,Kasuya K,Fujiyama S,Sezaki H,Hosaka T,Saitoh S,Kobayashi M,Kobayashi M,Arase Y,Ikeda K,Suzuki F,Suzuki Y,Kumada H.	The Lack of Hepatocyte Steatosis in Adult-onset Type II Citrullinemia Patients as Assessed by 7-year Interval Paired Biopsies.	Intern Med	58(13)	1891-1895	2019	
51) Suzuki H,Sezaki H,Suzuki F,Kasuya K,Sano T,Fujiyama S,Kawamura Y,Hosaka T, <u>Akuta N</u> ,Saitoh S,Kobayashi M,Arase Y,Ikeda K,Suzuki Y,Kumada H.	Real-world effects of long-term rifaximin treatment for Japanese patients with hepatic encephalopathy.	Hepatol Res	49(12)	1406-1413	2019	
52) Takeuchi Y, <u>Akuta N</u> ,Sezaki H,Suzuki F,Fujiyama S,Kawamura Y,Hosaka T,Kobayashi M,Kobayashi M,Saitoh S,Suzuki Y,Arase Y,Ikeda K,Kumada H	Efficacy and safety of elbasvir plus grazoprevir combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.	Hepatol Res	49(3)	256-263	2019	
53) Tanaka T, Miwa K, Fukahori M, Yomoda T, Sakaue T, Nagasu S, Ushijima T, Koga H, <u>Torimura T</u>	A Case of Chemotherapy-Induced Hyperammonemic Encephalopathy in a Patient with Metastatic Colon Cancer.	Gan to Kagaku Ryoho. Cancer & Chemotherapy	46 巻, 2 号	259-262	2019	

発表者氏名		論文タイトル名	発表誌名	巻号	ページ	出版年	関連
54)	Ide T, Koga H, Nakano M, Hashimoto S, Yatsuhashi H, Higuchi N, Nakamuta M, Oeda S, Eguchi Y, Shakado S, Sakisaka S, Yoshimaru Y, Sasaki Y, Honma Y, Harada M, Seike M, Maeshiro T, Miura S, Nakao K, Mawatari S, Ido A, Nagata K, Matsumoto S, Takami Y, Sohda T, Kakuma T, <u>Torimura T</u>	Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study	Hepatology International	13 巻, 3 号	293-301	2019	○
55)	Yoshitake M, Fukunaga S, <u>Torimura T</u>	Abdominal pain and prolonged fever of unknown cause in a 14-year-old boy	Gastroenterology	156 巻, 6 号	e1-e3	2019	
56)	Yamasaki H, Kinugasa T, Iwasaki S, Yoshioka S, Mizuochi T, Ishibashi M, Nagatsuka K, Yamauchi R, Ishibashi N, Araki T, Mori A, Akagi Y, Mitsuyama K, <u>Torimura T</u>	Questionnaire Survey from the 1st Kurume University Inflammatory Bowel Disease Center Educational Lecture	The Kurume Medical Journal	65 巻, 3 号	109-112	2019	
57)	Sakaue T, Koga H, Iwamoto H, Nakamura T, Ikezono Y, Abe M, Wada F, Masuda A, Tanaka T, Fukahori M, Ushijima T, Mihara Y, Naitou Y, Okabe Y, Kakuma T, Ohta K, Nakamura K, <u>Torimura T</u>	Glycosylation of ascites-derived exosomal CD133 is a potential prognostic biomarker in patients with advanced pancreatic cancer	Medical Molecular Morphology	52 巻, 4 号	198-208	2019	
58)	Yamasaki H, Mitsuyama K, Yoshioka S, Kuwaki K, Yamauchi R, Fukunaga S, Mori A, Tsuruta O, <u>Torimura T</u>	Leukocyte Apheresis Using a Fiber Filter Suppresses Colonic Injury Through Calcitonin Gene-Related Peptide Induction	Inflammatory bowel diseases	In press		2019	
59)	安元真希子、荒木俊博、岡部義信、新関 敬、城野智毅、石田祐介、牛島知之、阪上尊彦、鶴田 修、 <u>鳥村拓司</u>	巨大総胆管結石に併発した膵十二指腸動脈瘤破裂による胆道出血の 1 救命例	日本消化器病学会雑誌	117 巻, 1 号	92-98	2019	
60)	永松あゆ、川口 巧、神谷俊次、広田桂介、中野 暖、橋田竜騎、松瀬博夫、多賀百香、居石哲治、志波直人、 <u>鳥村拓司</u> 、八木 実	肝臓病と栄養療法	Journal of Clinical Rehabilitation	28 巻, 1 号	70-75	2019	
61)	広田桂介、川口 巧、橋田竜騎、永松あゆ、神谷俊次、中野暖、松瀬博夫、志波直人、 <u>鳥村拓司</u>	【特集：肝疾患におけるサルコペニア】サルコペニア治療とマネジメント	消化器・肝臓内科	5 巻, 1 号	103-110	2019	
62)	永田 務、鶴田 修、草場喜雄、森田 拓、中根智幸、大内彬弘、徳安秀紀、福永秀平、火野坂淳、向笠道太、江森啓悟、上野恵里奈、河野弘志、光山慶一、 <u>鳥村拓司</u>	大腸 NBI 拡大観察の基本と最新知見	胃と腸	54 巻, 1 号	9-16	2019	
63)	川口 巧、中野 暖、 <u>鳥村拓司</u>	肝性脳症の発症機序と誘発因子—最近の考え方—	肝胆膵	78 巻, 3 号	355-360	2019	

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
64) 大内彬弘、鶴田 修、荒木俊博、長 知徳、草場喜雄、中根智幸、徳安秀紀、永田 務、福永秀平、火野坂淳、向笠道太、江森啓悟、上野恵里奈、河野弘志、光山慶一、 <u>鳥村拓司</u>	PG type と NPG type 隆起型早期大腸癌における生物学的悪性度の相違	胃と腸	54 巻, 6 号	889-896	2019	
65) 神谷俊次、川口 巧、橋田竜騎、志波直人、 <u>鳥村拓司</u>	サルコペニアは脂肪肝でも重要	内科	123 巻, 5 号	1147-1149	2019	
66) 岡部義信、牛島知之、安元真希子、石田祐介、阪上尊彦、深堀理、島松 裕、寺部寛哉、鶴田修、 <u>鳥村拓司</u>	悪性胆道狭窄ステントのステント機能不全に対する内視鏡的対処法	消化器内視鏡	31 巻, 5 号	806-811	2019	
67) 河野弘志、鶴田 修、上野恵里奈、菅原脩平、後藤諒介、深水航、柴田 翔、渡邊裕次郎、山田康正、伊藤陽平、小林起秋、光山慶一、 <u>鳥村拓司</u>	主題：隆起型早期大腸癌の病態と診断 PG type 隆起型早期大腸癌の内視鏡診断 通常内視鏡観察の立場から	胃と腸	54 巻, 2 号	847-858	2019	
68) 川口 巧、 <u>鳥村拓司</u>	脂肪肝・NASH の人種差とやせ型 NASH	Medical Practice	36 巻, 9 号	1395-1399	2019	
69) 川口 巧、角田圭雄、 <u>鳥村拓司</u>	NAFLD/NASH の薬物療法の現状と展望	Pharma Medica	37 巻, 19 号	55-59	2019	
70) 岡部義信、牛島知之、安元真希子、石田祐介、阪上尊彦、深堀理、島松 裕、寺部寛哉、鶴田修、 <u>鳥村拓司</u>	胆管結石除去時のトラブルシューティング-結石除去の工夫とバスケット嵌頓時の対応について-	消化器内視鏡	31 巻, 11 号	1677-1683	2019	
71) 中野 暖、山村咲良、川口巧、 <u>鳥村拓司</u>	基礎疾患を有する NAFLD/NASH の治療	消化器の臨床	22 巻, 4 号	303-308	2019	
72) Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, <u>Hino K</u> , Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Jphnson P, Arai Y.	Randomised multicenter prospective trial of TACE plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma.	Gut	(in press)		2020	
73) Nishina S, Yamauchi A, Kawaguchi T, Kaku K, Goto M, Sasaki K, Hara Y, Tomiyama Y, Kuribayashi F, Torimura T, <u>Hino K</u> .	Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice.	Cell Mol Gastroenterol Hepatol	7	115-134	2019	
74) <u>Hino K</u> , Nishina S, Sasaki K, Hara Y.	Mitochondrial damage and iron metabolic dysregulation in hepatitis C virus infection.	Free Radic Biol Med	133	193-199	2019	
75) Harigae H, <u>Hino K</u> , Toyokuni S.	Iron soul of life on earth revised: From chemical reaction, ferroptosis to therapeutics.	Free Radic Biol Med	133	1-2	2019	



	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
76)	Nishida N, Sugiyama M, Sawai H, Nishina S, Sakai A, Ohashi J, Khor SS, Kakisaka K, Tsuchiya T, <u>Hino K</u> , Sumazaki R, Takikawa Y, Murata K, Kanda T, Yokosuka O, Tokunaga K, Mizokami.	Key HLA-DRB1-DQB1 haplotypes and role of the BTNL2 gene for response to hepatitis B vaccine.	Hepatology	68	848-858	2018	
77)	<u>Miyasaka A</u> , Yoshida Y, Suzuki A, Ueda H, Morino Y, Takikawa Y.	A case of suspected portal-pulmonary hypertension due to hepatitis C virus infection.	Clin J Gastroenterol.	13(1)	90-96	2020	○
78)	<u>Miyasaka A</u> , Yoshida Y, Wang T, Takikawa Y.	Next-generation sequencing analysis of the human T-cell and B-cell receptor repertoire diversity before and after hepatitis B vaccination.	Hum Vaccin Immunother.	15(11)	2738-2753	2019	
79)	Kakisaka K, Sakai A, Yoshida Y, <u>Miyasaka A</u> , Takahashi F, Sumazaki R, Takikawa Y.	Hepatitis B Surface Antibody Titers at One and Two Years after Hepatitis B Virus Vaccination in Healthy Young Japanese Adults.	Intern Med.	58(16)	2349-2355	2019	
80)	Murai K, Honda M, Shirasaki T, <u>Shimakami T</u> , Omura H, Misu H, Kita Y, Takeshita Y, Ishii KA, Takamura T, Urabe T, Shimizu R, Okada H, Yamashita T, Sakai Y, Kaneko S.	Induction of Selenoprotein P mRNA during Hepatitis C Virus Infection Inhibits RIG-I-Mediated Antiviral Immunity.	Cell Host Microbe.	25(4)	588-601	2019	
81)	Doncheva NT, Domingues FS, McGivern DR, <u>Shimakami T</u> , Zeuzem S, Lengauer T, Lange CM, Albrecht M, Welsch C.	Near-Neighbor Interactions in the NS3-4A Protease	J Mol Biol.	431(12)	2354-2368	2019	
82)	Omura H, Liu F, <u>Shimakami T</u> , Murai K, Shirasaki T, Kitabayashi J, Funaki M, Nishikawa T, Nakai R, Sumiyadorj A, Hayashi T, Yamashita T, Honda M, Kaneko S.	Establishment and Characterization of a New Cell Line Permissive for Hepatitis C Virus Infection.	Sci Rep.	9(1)	7943-	2019	
83)	Horii R, Honda M, Shirasaki T, <u>Shimakami T</u> , Shimizu R, Yamanaka S, Murai K, Kawaguchi K, Arai K, Yamashita T, Sakai Y, Yamashita T, Okada H, Nakamura M, Mizukoshi E, Kaneko S.	MicroRNA-10a Impairs Liver Metabolism in Hepatitis C Virus-Related Cirrhosis Through Deregulation of the Circadian Clock Gene Brain and Muscle Aryl Hydrocarbon Receptor Nuclear Translocator-Like 1.	Hepatol Commun.	3(12)	1687-1703.	2019	
84)	Miyazaki T, Sasaki S, Toyoda A, Shirai M, <u>Ikegami T</u> , Matsuzaki Y, Honda A	Influences of taurine deficiency on bile acids of the bile in the cat model	Adv Exp Med Biol.	1155	35-44	2019	
85)	Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, <u>Ikegami T</u> , Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K	"The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.	Aliment Pharmacol Ther.	49(9)	1230-1241	2019	○
86)	Itokawa N, Atsukawa M, Tsubota A, <u>Ikegami T</u> , Shimada N, Kato K, Abe H, Okubo T, Arai T, Iwashita AN, Kondo C, Mikami S, Asano T, Matsuzaki Y, Toyoda H, Kumada T, Iio E, Tanaka Y, Iwakiri K	Efficacy of direct-acting antiviral treatment in patients with compensated liver cirrhosis: A multicenter study	Hepatol Res.	49(2)	125-135	2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
87)	Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, <u>Iked</u> <a href="#">Iked</a> <u>H</u> , Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan	Hepatol Res.	49(4)	369-376	2019	○
88)	Miyazaki T, Honda A, <u>Ikegami T</u> , Iida T, Matsuzaki Y	Human-specific dual regulations of FXR-activation for reduction of fatty liver using in vitro cell culture model	J Clin Biochem Nutr	64(2)	112-123	2019	
89)	Toyoda H, Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N20, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, <u>Ikegami T</u> , Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T	Real-world experience of 12-week DAA regimen of glecaprevir and pibrentasvir in patients with chronic HCV infection	J Gastroenterol Hepatol.	[Epub ahead of print]		2019	○
90)	Iked <a href="#">Iked</a> <u>H</u> , Watanabe T, Atsukawa M, Toyoda H, Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, <u>Ikegami T</u> , Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T	Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan	Journal of Viral Hepatitis	26(11)	1266-1275	2019	○
91)	Toyoda H, Atsukawa M, Uojima H, Nozaki A, Tamai H, Takaguchi K, Fujioka S, Nakamuta M, Tada T, Yasuda S, Chuma M, Senoh T, Tsutsui A, Yamashita N, Hiraoka A, Michitaka K, Shima T, Akahane T, Itobayashi E, Watanabe T, Ikeda H, Iio E, Fukunishi S, Asano T, Tachi Y, <u>Ikegami T</u> , Tsuji K, Abe H, Kato K, Mikami S, Okubo H, Shimada N, Ishikawa T, Matsumoto Y, Itokawa N, Arai T, Tsubota A, Iwakiri K, Tanaka Y, Kumada T	Trends and Efficacy of Interferon-Free Anti-hepatitis C Virus Therapy in the Region of High Prevalence of Elderly Patients, Cirrhosis, and Hepatocellular Carcinoma: A Real-World, Nationwide, Multicenter Study of 10 688 Patients in Japan	Open Forum Infect Dis.	6(5)	6.ofz185	2019	○
92)	Yara S, <u>Ikegami T</u> , Miyazaki T, Murakami M, Iwamoto J, Hirayama T, Kohjima M, Nakamuta M, Honda A	Circulating bile acid profiles in Japanese patients with NASH	GastroHep	1	in press	2019	
93)	Honda A, Miyazaki T, Iwamoto J, Hirayama T, Morishita Y, Monma T, Ueda H, Mizuno S, Sugiyama F, Takahashi S, <u>Ikegami T</u>	Regulations of bile acid metabolism in mouse models with hydrophobic bile acid composition	J Lipid Res.		Epub ahead of print	2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
94)	上田元, 岩本淳一, 林明慶, 門馬匡邦, 村上昌, 玉虫惇, 小西直樹, 屋良昭一郎, 平山剛, 本多彰, <u>池上正</u>	出血性消化管病変を呈した Anaphylactoid 紫斑病の一例	Progress of Digestive Endoscopy	94(1)	78-80	2019	
95)	<u>池上正</u> , 屋良昭一郎, 村上昌, 岩本淳一, 宮崎照雄, 本多彰	消化器生活習慣病における酸化ステロールの意義. 特集: 胆汁酸とアンチエイジング	日本抗加齢学会雑誌	15(2)	180-186	2019	
96)	岩本淳一, 門馬匡邦, 上田元, 村上昌, 宮崎照雄, <u>池上正</u> , 本多彰, 松崎靖司	胆汁酸と消化吸収	消化器・肝臓内科	5(5)	498-504	2019	
97)	Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, Fujii H, Wu Y, Kam LY, Ji F, Li X, Chien N, Wei M, Ogawa E, Zhao C, Wu X, Stave CD, Henry L, Barnett S, Takahashi H, Furusyo N, Eguchi Y, Hsu YC, Lee TY, Ren W, Qin C, Jun DW, <u>Toyoda H</u> , Wong VWS, Cheung R, Zhu Q, Nguyen MH	Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis of 237 studies and 13,044,518 individuals from 16 countries/regions	Lancet Gastroenterol Hepatol		in press		
98)	Takaguchi K, <u>Toyoda H</u> , Tsutui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H	Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan	J Gastroenterol		in press		○
99)	Chuma M, <u>Toyoda H</u> , Matsuzaki J, Saito Y, Kumada T, Tada T, Kaneoka Y, Maeda A, Yokoo H, Ogawa K, Kamiyama T, Taketomi A, Matsuno Y, Yazawa K, Takeda K, Kunisaki C, Ogushi K, Moriya S, Hara K, Nozaki A, Kondo M, Fukuda H, Numata K, Takana K, Maeda S, Sakamoto N	Circulating microRNA-1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinoma	Hepatol Res		in press		
100)	<u>Toyoda H</u> , Tada T, Yasuda S, Mizuno K, Ito T, Kumada T	Dynamic evaluation of liver fibrosis to assess the risk of hepatocellular carcinoma in patients with chronic hepatitis C who achieved sustained virologic response	Clin Infect Dis		in press		○
101)	Tada T, <u>Toyoda H</u> , Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J	Long-term prognosis of liver disease in patients with chronic hepatitis B virus infection receiving nucleos(t)ide analogue therapy: an analysis using a Markov chain model	Eur J Gastroenterol Hepatol		in press		○
102)	Mizuno K, <u>Toyoda H</u> , Yasuda S, Tada T, Kumada T, Sone Y, Tanaka J	The course of elderly patients with persistent hepatitis C virus infection without hepatocellular carcinoma	J Gastroenterol		in press		○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
103)	Ikeda H, Watanabe T, Atsukawa M, <u>Toyoda H</u> , Takaguchi K, Nakamuta M, Matsumoto N, Okuse C, Tada T, Tsutsui A, Yamashita N, Kondo C, Hayama K, Kato K, Itokawa N, Arai T, Shimada N, Asano T, Uojima H, Ogawa C, Mikami S, Ikegami T, Fukunishi S, Asai A, Iio E, Tsubota A, Hiraoka A, Nozaki A, Okubo H, Tachi Y, Moriya A, Oikawa T, Matsumoto Y, Tsuruoka S, Tani J, Kikuchi K, Iwakiri K, Tanaka Y, Kumada T, the KTK49 Liver Study Group	Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve non-cirrhotic genotype 1 and 2 HCV patients in a real-world setting in Japan	J Viral Hepat		in press		○
104)	Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kriyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, <u>Toyoda H</u> , Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Tanaka H, Tamai T, Koizumi Y, Hiasa Y, Michitaka K, Kudo M	Important clinical factors in sequential therapy including lenvatinib against unresectable hepatocellular carcinoma	Oncology		in press		
105)	Tada T, <u>Toyoda H</u> , Yasuda S, Miyake N, Kumada T, Kurisu A, Ohisa M, Akita T, Tanaka J. Natural history of liver-related disease in patients with chronic hepatitis C virus infection: an analysis using a Markov chain model	Natural history of liver-related disease in patients with chronic hepatitis C virus infection: an analysis using a Markov chain model	J Med Virol		in press		○
106)	Huang CF, Iio E, Jun DW, Ogawa E, <u>Toyoda H</u> , Hsu YC, Haga H, Iwane S, Enomoto M, Lee DH, Wong G, Liu CH, Tada T, Chuang WL, Cheung R, Hayashi J, Tseng CH, Yasuda S, Tran S, Kam L, Henry L, Jeong JY, Nomura H, Park SH, Nakamuta M, Huang JF, Tai CM, Lo GH, Lee MH, Yang HI, Kao JH, Tamori A, Eguchi Y, Ueno Y, Furusyo N, Tanaka Y, Yu ML, Nguyen MH for the REAL-C Investigators	Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C Consortium	Hepatol Int		in press		○
107)	Han GH, Berhane S, <u>Toyoda H</u> , Bettinger D, Elshaarawy O, Chan AWH, Kirstein M, Mosconi C, Hucke F, Palmer D, Pinato DJ, Sharma R, Ottaviani D, Jang JW, Labeur TA, van Delden OM, Pirisi M, Stern N, Sangro B, Meyer T, Fateen W, Garcia-Finana M, Gooma A, Waked I, Rewisha E, Aithal GP, Travis S, Kudo M, Cucchetti A, Peck-Radosavljevic M, Takkenberg RB, Chan SL, Vogel A, Johnson PJ	Prediction of survival among patients receiving transarterial chemoembolization: a response-based approach	Hepatology		in press		

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
108)	Kariyama K, Nouse K, Wakuta A, Oonishi A, <u>Toyoda H</u> , Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Takaguchi K, Tsutsui A, Shimada N, Kumada T	Treatment of intermediate-stage hepatocellular carcinoma in Japan: position of curative therapies	Liver Cancer		in press		
109)	Nouse K, Furubayashi Y, Shiota S, Miyake N, Oonishi A, Wakuta A, Kariyama K, Hiraoka A, Tsuji K, Itobayashi E, Shimada N, Ishikawa T, Tachi Y, Tada T, <u>Toyoda H</u> , Kumada T	Early detection of hepatocellular carcinoma in patients with diabetes mellitus	Eur J Gastroenterol Hepatol		in press		
110)	Hsu YC, Wong GLH, Chen CH, Peng CY, Yeh ML, Cheung KS, <u>Toyoda H</u> , Huang CF, Trinh H, Xie Q, Enomoto M, Liu L, Yasuda S, Tanaka Y, Kozuka R, Tsai PC, Huang YT, Wong C, Huang R, Jang TY, Hoang J, Yang HI, Li J, Lee DH, Takahashi H, Zhang JQ, Ogawa E, Zhao C, Liu C, Furusyo N, Eguchi Y, Wong C, Wu C, Kumada T, Yuen MF, Yu ML, Nguyen MH	Tenofovir versus entecavir for hepatocellular carcinoma prevention in an international consortium of chronic hepatitis B	Am J Gastroenterol		in press		
111)	Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, <u>Toyoda H</u> , Kumada T, Fujishiro M	Serum nutritional markers as prognostic factor for hepatic and extrahepatic carcinogenesis in Japanese patients with nonalcoholic fatty liver disease	Nutr Cancer		in press		
112)	Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tsutsui A, Shibata H, Tada T, <u>Toyoda H</u> , Nouse K, Itokawa N, Joko K, Hiasa Y, Michitaka K, Imai M, Atsukawa M, Hayama K, Nagano T, Koizumi Y, Fukunishi S, Yokohama K, Kudo M, Arai T	Post-progression treatment eligibility of unresectable hepatocellular carcinoma patients treated with lenvatinib	Liver Cancer		in press		
113)	Hiraoka A, Kumada T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Tada T, <u>Toyoda H</u> , Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y, Michitaka K	Early relative change in hepatic function with lenvatinib for unresectable hepatocellular carcinoma	Oncology		in press		
114)	Dang H, Yeo YH, Yasuda S, Huang CF, Iio E, Landis C, Jun DW, Enomoto M, Ogawa E, Tsai PC, Le A, Liu M, Maeda M, Nguyen B, Ramrakhiani N, Henry L, Cheung R, Tamori A, Kumada T, Tanaka Y, Yu ML, <u>Toyoda H</u> , Nguyen MH	Cure with interferon free DAA is associated with increased survival in patients with HCV related HCC from both East and West	Hepatology		in press		○
115)	Tada T, Kumada T, Hiraoka A, Michitaka K, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, <u>Toyoda H</u> , Nouse K, Tsutsui A, Nagano T, Itokawa N, Hayama K, Imai M, Joko K, Koizumi Y, Hiasa Y	Safety and efficacy of lenvatinib in elderly patients with unresectable hepatocellular carcinoma: a multicenter analysis with propensity score matching	Hepatol Res		in press		

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
116) Yang HI, Yeh ML, Wong GL, Peng CY, Chen CH, Trinh HN, Cheung KS, Xie Q, Su TH, Kozuka R, Lee DH, Ogawa E, Zhao C, Ning HB, Huang R, Li J, Zhang JQ, Ide T, Xing H, Iwane S, Takahashi H, Wong C, Wong C, Lin CH, Hoang J, Ie A, Henry L, <u>Toyoda H</u> , Ueno Y, Gane EJ, Eguchi Y, Kurosaki M, Wu C, Liu C, Shang J, Furusyo N, Enomoto M, Kao JH, Yuen MF, Yu ML, Nguyen MH	REAL-B (Real-world Effectiveness from the Asia Pacific Rim Liver Consortium for HBV) risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy	J Infect Dis		in press		
117) <u>Toyoda H</u> , Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Tanaka Y, Iwakiri K, Kumada T	Real-world experience of 12-week DAA regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C	J Gastroenterol Hepatol		in press		○
118) Ogawa E, <u>Toyoda H</u> , Iio E, Jun DW, Huang CF, Enomoto M, Hsu YC, Haga H, Iwane S, Wong G, Lee DH, Tada T, Liu CH, Chuang WL, Hayashi J, Cheung R, Yasuda S, Tseng CH, Takahashi H, Tran S, Yeo YH, Henry L, Barnett SD, Nomura H, Nakamuta M, Dai CY, Huang JF, Yang HI, Lee MH, Jun MJ, Kao JH, Eguchi Y, Ueno Y, Tamori A, Furusyo N, Yu ML, Tanaka Y, Nguyen MH for the REAL-C Investigators	HCV cure rates are reduced in patients with active but not inactive hepatocellular carcinoma- a practice implication	Clin Infect Dis		in press		○
119) Tada T, Kumada T, <u>Toyoda H</u> , Yasuda S, Sone Y, Hashinokuchi S, Ogawa S, Oguri T, Kamiyama N, Chuma M, Akita T, Tanaka J	Liver stiffness does not affect ultrasound-guided attenuation coefficient measurement in the evaluation of hepatic steatosis	Hepatol Res		in press		
120) Itami-Matsumoto S, Hayakawa M, Uchida-Kobayashi S, Enomoto M, Tamori A, Mizuno K, <u>Toyoda H</u> , Tamura T, Akutsu T, Ochiya T, Kawada N, Murakami Y	Circulating exosomal miRNA profiles predict the occurrence and recurrence of hepatocellular carcinoma in patients with direct-acting antiviral-induced sustained viral response	Biomedicines		in press		
121) Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Ishikawa T, <u>Toyoda H</u> , Kumada T, Fujishiro M.	Correlation of serum zinc levels with pathological and laboratory findings in patients with nonalcoholic fatty liver disease	Eur J Gastroenterol Hepatol		in press		

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
122)	Best J, Bechmann LP, Sowa JP, Sydor S, Dechene A, Pflanz K, Bedreli S, Schotten C, Geier A, Berg T, Fischer J, Vogel A, Bantel H, Weinmann A, Schattenberg JM, Huber Y, Wege H, von Felden J, Schulze K, Bettinger D, Thimme R, Sinner F, Schutte K, Weiss KH, <u>Toyoda H</u> , Yasuda S, Kumada T, Berhane S, Wichert M, Heider D, Gerken G, Johnson PJ, Canbay A	GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis	Clin Gastroenterol Hepatol		in press		
123)	Shimizu Y, Mizuno S, Fujinami N, Suzuki T, Saito K, Konishi M, Takahashi S, Gotohda N, Tada T, <u>Toyoda H</u> , Kumada T, Miura M, Suto K, Yamaji T, Matsuda T, Endo I, Nakatsura T	Plasma and tumoral glypican-3 levels are correlated in patients with hepatitis C virus-related hepatocellular carcinoma	Cancer Sci		in press		
124)	Cucchetti A, Zhong J, Berhane S, <u>Toyoda H</u> , Shi KQ, Tada T, Chong CCN, Xiang BD, Li LQ, Lai PBS, Ercolani G, Mazzaferro V, Kudo M, Cescon M, Pinna AD, Kumada T, Johnson PJ	The chances of hepatic resection curing hepatocellular carcinoma	J Hepatol		in press		
125)	Atsukawa M, Tsubota A, Takaguchi K, <u>Toyoda H</u> , Iwasa M, Ikegami T, Chuma M, Nozaki A, Uojima H, Hiraoka A, Fukunishi S, Yokohama K, Tada T, Kato K, Abe H, Tani J, Okubo H, Watanabe T, Hattori N, Tsutsui A, Senoh T, Yoshida Y, Okubo T, Itokawa N, Nakagawa-Iwashita A, Kondo C, Arai T, Michitaka K, Iio E, Kumada T, Tanaka Y, Takei Y, Iwakiri K	Analysis of factors associated with the prognosis of cirrhotic patients who were treated with tolvaptan for hepatic edema	J Gastroenterol Hepatol		in press		
126)	<u>Toyoda H</u> , Atsukawa M, Watanabe T, Nakamuta M, Uojima H, Nozaki A, Takaguchi K, Fujioka S, Iio E, Shima T, Akahane T, Fukunishi S, Asano T, Michitaka K, Tsuji K, Abe H, Mikami S, Okubo H, Okubo T, Shimada N, Ishikawa T, Moriya A, Tani J, Morishita A, Ogawa C, Tachi Y, Ikeda H, Yamashita N, Yasuda S, Chuma M, Tsutsui A, Hiraoka A, Ikegami T, Genda T, Tsubota A, Masaki T, Iwakiri K, Kumada T, Tanaka Y, Okanoue T	Marked heterogeneity in the diagnosis of compensated cirrhosis of patients with chronic HCV infection in a real-world setting: a large, multicenter study from Japan	J Gastroenterol Hepatol		in press		○
127)	Nozaki A, Atsukawa M, Kondo C, <u>Toyoda H</u> , Chuma M, Nakamuta M, Uojima H, Takaguchi K, Ikeda H, Watanabe T, Ogawa S, Itokawa N, Arai T, Hiraoka A, Asano T, Fujioka S, Ikegami T, Shima T, Ogawa C, Akabane T, Shimada N, Fukunishi S, Abe H, Tsubota A, Genda T, Okubo H, Mikami S, Morishita A, Moriya A, Tani J, Tachi Y, Hotta N, Ishikawa T, Okanoue T, Tanaka Y, Kumada T, Iwakiri K, Maeda S	The effectiveness and safety of glecaprevir/pibrentasvir in chronic hepatitis C patients with refractory factors in the real world: A comprehensive analysis of a prospective multicenter study	Hepatol Int		in press		○

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
128)	Taylor RS, Taylor RJ, Bayliss S, Hagstrom H, Nasr P, Schattenberg JM, Ishigami M, <u>Toyoda H</u> , Wong VWS, Peleg N, Shlomain A, Sebastiani G, Seko Y, Bhala N, Younossi ZM, Anstee QM, McPherson S, Newsome PN	Association between fibrosis stage and outcomes of patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis	Gastroenterology		in press		
129)	Chuma M, Uojima H, Numata K, Hidaka H, <u>Toyoda H</u> , Hiraoka A, Tada T, Hirose S, Atsukawa M, Itokawa N, Arai T, Kako M, Nakazawa T, Wada N, Iwasaki S, Miura Y, Hishiki S, Nishigori S, Morimoto M, Hattori N, Ogushi K, Nozaki A, Fukuda H, Kagawa T, Michitaka K, Kumada T, Maeda S	Early changes in circulating FGF19 and Ang-2 levels as possible predictive biomarkers of clinical response to lenvatinib therapy in hepatocellular carcinoma	Cancers (Basel)		in press		
130)	<u>Toyoda H</u> , Yasuda S, Kumada T	Editorial: the emergence of nonhypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C – authors' reply	Aliment Pharmacol Ther	51	169-170	2020	○
131)	Hiraoka A, Kumada T, Tsuji K, Takaguchi K, Itobayashi E, Kariyama K, Ochi H, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Tachi Y, Tada T, <u>Toyoda H</u> , Nouse K, Joko K, Hiasa Y, Michitaka K, Kudo M.	Validation of modified ALBI grade for more detailed assessing hepatic function of hepatocellular carcinoma – multicenter analysis.	Liver Cancer	8	121-129	2019	
132)	Hiraoka A, Kumada T, Ogawa C, Kariyama K, Morita M, Nouse K, <u>Toyoda H</u> , Tada T, Ochi M, Murakami T, Izumoto H, Ueki H, Kitahata S, Aibiki T, Okudaira T, Yomago H, Iwasaki R, Tomida H, Miyamoto Y, Mori K, Miyata H, Tsubouchi E, Kishida M, Ninomiya T, Michitaka K	Proposed a simple score for recommendation of scheduled ultrasonography surveillance for hepatocellular carcinoma after Direct Acting Antivirals: multicenter analysis	J Gastroenterol Hepatol	34	436-441	2019	
133)	Atsukawa M, Tsubota A, <u>Toyoda H</u> , Takaguchi K, Kondo C, Okubo T, Hiraoka A, Michitaka K, Fujioka S, Uojima H, Watanabe T, Ikeda H, Asano T, Ishikawa T, Matsumoto Y, Abe H, Kato K, Tsuji K, Ogawa C, Shimada N, Iio E, Mikami S, Tanaka Y, Kumada T, Iwakiri K	Efficacy and safety of elbasvir/grazoprevir for Japanese patients with genotype 1b chronic hepatitis C complicated by chronic kidney disease, including those undergoing hemodialysis: a post-hoc analysis of a multicenter study	J Gastroenterol Hepatol	34	364-369	2019	○
134)	Ito T, Ishigami M, Ishizu Y, Kuzuya T, Honda T, Hayashi K, Nishimura D, <u>Toyoda H</u> , Kumada T, Goto H, Hirooka Y	Utility and limitations of non-invasive fibrosis markers for predicting prognosis in biopsy-proven Japanese NAFLD patients	J Gastroenterol Hepatol	34	207-214	2019	
135)	Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Itobayashi E, Shimada N, Tajiri K, Tsuji K, Ishikawa T, Ochi H, Hirooka M, Tsutsui A, Shibata H, Tada T, <u>Toyoda H</u> , Nouse K, Joko K, Hiasa Y, Michitaka K	Therapeutic potential of lenvatinib for unresectable hepatocellular carcinoma in clinical practice: multicenter analysis	Hepatol Res	49	111-117	2019	



発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
136) Itokawa N, Atsukawa M, Tsubota A, Ikegami T, Shimada N, Kato K, Abe H, Okubo T, Arai T, Nakagawa-Iwashita A, Kondo C, Mikami S, Asano T, Matsuzaki Y, <u>Toyoda H</u> , Kumada T, Iio E, Tanaka Y, Iwakiri K.	Efficacy of direct-acting antivirals treatment in patients with compensated liver cirrhosis: a multicenter study	Hepatol Res	49	125-135	2019	○
137) <u>Toyoda H</u> , Kumada T, Tada T, Mizuno K, Sone Y, Akita Y, Tanaka J, Johnson PJ	The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: a prospective observational study	Liver Int	39	448-454	2019	○
138) <u>Toyoda H</u>	Direct-acting antiviral therapy for chronic HCV genotype 4 infection: exploring new regimens	Health Sci Rep	2	e106	2019	○
139) Tada T, Kumada T, <u>Toyoda H</u> , Kobayashi N, Sone Y, Oguri T, Kamiyama N	Utility of attenuation coefficient measurement using an ultrasound-guided attenuation parameter for evaluation of hepatic steatosis: comparison with MRI-determined proton density fat fraction	Am J Roentgenol	212	332-341	2019	
140) Atsukawa M, Tsubota A, <u>Toyoda H</u> , Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K	Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan	Hepatol Res	49	369-376	2019	○
141) Hiraoka A, Kumada T, Kariyama K, Takaguchi K, Atsukawa M, Itobayashi E, Tsuji K, Tajiri K, Hirooka M, Shimada N, Ishikawa T, Ochi H, Tada T, <u>Toyoda H</u> , Nouse K, Tsutsui A, Itokawa N, Imai M, Joko K, Hiasa Y, Michitaka K	Clinical features of lenvatinib for unresectable hepatocellular carcinoma in real-world conditions – multicenter analysis	Cancer Med	8	137-146	2019	
142) Tada T, Kumada T, <u>Toyoda H</u> , Tsuji K, Hiraoka A, Michitaka K, Deguchi A, Ishikawa T, Imai M, Ochi H, Joko K, Shimada N, Tajiri K, Hirooka M, Koizumi Y, Hiasa Y, Tanaka J	Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: an analysis using time-dependent receiver operating characteristic	J Gastroenterol Hepatol	34	1066-1073	2019	
143) Nakashima M, <u>Toyoda H</u> , Tada T, Mizuno K, Iio E, Tanaka Y, Sugiyama T, Yoshimura T, Kumada T	Influence of renal dysfunction on dose reduction and virological efficacy of regimens combining ribavirin and all-oral direct acting antivirals in patients with chronic hepatitis C virus infection	Hepatol Res	49	512-520	2019	○
144) Kariyama K, Nouse K, <u>Toyoda H</u> , Tada T, Hiraoka A, Tsuji K, Itobayashi E, Ishikawa T, Wakuta A, Oonishi A, Kumada T, Kudo M	Utility of FIB-4-T as a prognostic factor for hepatocellular carcinoma	Cancers (Basel)	11	E203	2019	

	発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年	関連
145)	Atsukawa M, Tsubota A, <u>Toyoda H</u> , Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K	The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study	Aliment Pharmacol Ther	49	1230-1241	2019	○
146)	Amoros R, King R, <u>Toyoda H</u> , Kumada T, Johnson PJ, Bird TG	A continuous-time hidden Markov model for cancer surveillance using serum biomarkers with application to hepatocellular carcinoma	METRON	77	67-86	2019	
147)	Tada T, Kumada T, <u>Toyoda H</u> , Yasuda S, Koyabu T, Nakashima M	Impact of branched-chain amino acid granule therapy in patients with hepatocellular carcinoma who have normal albumin levels and low branched-chain amino acid to tyrosine ratios	Nutr Cancer	6	1-10	2019	
148)	Nakamura S, Nouse K, Okada H, Onishi H, Fujioka S, Araki Y, Iwadou S, Kumada T, <u>Toyoda H</u> , Motomura K, Kariyama K, Kobashi H, Kaneyoshi T, Ando M, Moriya A, Taniguchi H, Morimoto Y, Hagihara H, Tanaka M	Hepatocellular carcinoma recurrence in HCV patients treated with direct-acting antivirals after curative treatment	Hepatoma Res	5	16	2019	○
149)	<u>Toyoda H</u> , Tada T, Yasuda S, Mizuno K, Sone Y, Kaneoka Y, Maeda A, Akita T, Tanaka J, Kumada T	The emergence of non-hypervascular hypointense nodules on Gd-EOB-DTPA-enhanced MRI in patients with chronic hepatitis C	Aliment Pharmacol Ther	50	1232-1238	2019	○
150)	Imai K, Takai K, Miwa T, Taguchi D, Hanai T, Suetsugu A, Shiraki M, <u>Shimizu M</u> .	Rapid depletions of subcutaneous fat mass and skeletal muscle mass predict worse survival in patients with hepatocellular carcinoma treated with sorafenib.	Cancers (Basel)	11	1206	2019	
151)	Imai K, Takai K, Hanai T, Suetsugu A, Shiraki M, <u>Shimizu M</u> .	Homeostatic model assessment of insulin resistance for predicting the recurrence of hepatocellular carcinoma after curative treatment.	Int J Mol Sci	20	E605	2019	
152)	Hanai T, Shiraki M, Miwa T, Watanabe S, Imai K, Suetsugu A, Takai K, Moriwaki H, <u>Shimizu M</u> .	Effect of loop diuretics on skeletal muscle depletion in patients with liver cirrhosis.	Hepatol Res	49	82-95	2019	
153)	Hanai T, Shiraki M, Watanabe S, Imai K, Suetsugu A, Takai K, Moriwaki H, <u>Shimizu M</u> .	Prognostic significance of minimal hepatic encephalopathy in patients with liver cirrhosis in Japan: A propensity score-matching analysis.	J Gastroenterol Hepatol	34	1809-1816	2019	